Today: 29 June 2026
Browse Category

LSE:GSK 6 January 2026 - 30 January 2026

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

GSK stock in focus as EU expands Arexvy RSV vaccine approval to all adults 18+

London, Jan 26, 2026, 07:59 GMT — Premarket GSK announced that the European Commission has greenlit its RSV vaccine Arexvy for adults 18 and older, expanding eligibility beyond those 60-plus and high-risk individuals aged 50 to 59. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, GSK’s head of Vaccines and Infectious Diseases R&D. The approval applies across EU member states and countries in the European Economic Area. GSK pointed to an average of 158,000 RSV-related adult hospitalisations annually within the EU.
26 January 2026
··
GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next

GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next

London, Jan 25, 2026, 07:55 GMT — Market closed Shares of GSK plc are set to draw attention when London trading resumes Monday, following news that China approved a new asthma indication for its Trelegy Ellipta inhaler. On Friday, the stock closed down 3.5 pence, or 0.19%, at 1,801 pence, with around 9 million shares changing hands.
25 January 2026
····
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

London, Jan 24, 2026, 07:58 GMT — Market closed GSK plc shares slipped 0.2% to 1,801 pence on Friday following news that China approved Trelegy Ellipta for adults with uncontrolled asthma. With London trading closed for the weekend, investors will have to wait until Monday to assess the impact of the new label.
24 January 2026
·····
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

London, January 17, 2026, 07:58 GMT — The market has closed. Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day average of 8.2 million.
17 January 2026
·····
GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

London, Jan 11, 2026, 08:35 GMT — The market has closed. Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the 1,830 pence level, close to the 200-day moving average, as a key support zone.
11 January 2026
··
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

London, Jan 7, 2026, 07:52 GMT — Premarket GSK said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24 weeks after treatment ends. GSK
7 January 2026
··
1 2 3 4

Stock Market Today

  • SPS Commerce (SPSC) Rallies 5.7% on Sale Rumors, Earnings in Focus
    June 29, 2026, 2:05 PM EDT. SPS Commerce (SPSC) closed up 5.7% at $58.87 after volume spiked and reports spread about a possible sale, tied to activist pressure for the company to consider strategic options. The supply chain software firm forecasts quarterly EPS of $1.08, up 8% from last year, and sees revenue at $195.14 million, up 4.1%. Consensus estimates for earnings didn't move in the last 30 days, which could cap upside ahead. SPSC sits at Zacks Rank #2 (Buy). Bowman Consulting (BWMN), another name in the group, climbed 2.3% but has seen its earnings estimates drop 14.6%; Zacks Rank is #3 (Hold). Market watching for shifts in earnings outlooks for clues on next moves.
Go toTop